Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.
Roeland E Wasmann, Cornelis Smit, Eric P H van Dongen, René M J Wiezer, Jill Adler-Moore, Yvo M de Beer, David M Burger, Catherijne A J Knibbe, Roger J M Brüggemann
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020 May 06In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104-177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively). Clinical Trials Registration NCT02320604. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Citation
Roeland E Wasmann, Cornelis Smit, Eric P H van Dongen, René M J Wiezer, Jill Adler-Moore, Yvo M de Beer, David M Burger, Catherijne A J Knibbe, Roger J M Brüggemann. Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020 May 06;70(10):2213-2215
Mesh Tags
Substances
PMID: 31588493
View Full Text
